Therefore, we used SK-Hep1/luc2 and Hep3B 2.1-7 tumor bearing mice to verify the effect of regorafenib on NF-κB-modulated tumor progression in HCC in vivo. Here, NFKB1 is linked to hepatocellular carcinoma.